EQS-Adhoc: RELIEF THERAPEUTICS Holding AG: Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Study results Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b

Related Keywords

Geneva ,Genè ,Switzerland ,Swiss ,Michael Miller ,Jack Weinstein ,Advita Lifescience Gmb ,Linkedin ,National Institutes Of Health ,Pharma Research ,Eqs Group ,Swiss Exchange ,Nrx Pharmaceuticals Inc ,Rx Communications Group ,Nasdaq ,Holding Ag Key ,National Institutes Of Health Sponsored ,Group News Service ,Announced Favorable New Safety Report ,Critical Care Study ,New Safety Report ,National Institutes ,Health Sponsored ,Critical Care Phase ,Independent Data Safety Monitoring Board ,Vasoactive Intestinal Peptide ,License Agreement ,Acer Therapeutics ,Urea Cycle Disorders ,Maple Syrup Urine ,Advita Lifescience Gmbh ,Financial Officer ,Adhoc ,Relief ,Herapeutics ,Molding ,Reports ,Collaboration ,Partner ,Nnounced ,Favorable ,Safety ,Report ,Aviptadil ,Sponsored ,Eactiv ,Critical ,Mare ,Study ,Patients ,Life ,Threatening ,O ,